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Abstract
Background: The precise mechanisms involved in the initiation and progression of rheumatoid arthritis (RA) are not known.
Early stages of RA often have non-specific symptoms, delaying diagnosis and therapy. Additionally, there are currently no
established means to predict clinical responsiveness to therapy. Immune cell activation is a critical component therefore we
examined the cellular activation of peripheral blood mononuclear cells (PBMCs) in the early stages of RA, in order to develop
a novel diagnostic modality.
Methods and Findings: PBMCs were isolated from individuals diagnosed with early RA (ERA) (n=38), longstanding RA
(n=10), osteoarthritis (OA) (n=19) and from healthy individuals (n=10). PBMCs were examined for activation of 15
signaling effectors, using phosphorylation status as a measure of activation in immunophenotyped cells, by flow cytometry
(phospho-flow). CD3+CD4+, CD3+CD8+ and CD20+ cells isolated from patients with ERA, RA and OA exhibited activation of
multiple phospho-epitopes. ERA patient PBMCs showed a bias towards phosphorylation-activation in the CD4+ and CD20+
compartments compared to OA PBMCs, where phospho-activation was primarily observed in CD8+ cells. The ratio of
phospho (p)-AKT/p-p38 was significantly elevated in patients with ERA and may have diagnostic potential. The mean
fluorescent intensity (MFI) levels for p-AKT and p-H3 in CD4+, CD8+ and CD20+ T cells correlated directly with physician
global assessment scores (MDGA) and DAS (disease activity score). Stratification by medications revealed that patients
receiving leflunomide, systemic steroids or anti-TNF therapy had significant reductions in phospho-specific activation
compared with patients not receiving these therapies. Correlative trends between medication-associated reductions in the
levels of phosphorylation of specific signaling effectors and lower disease activity were observed.
Conclusions: Phospho-flow analysis identified phosphorylation-activation of specific signaling effectors in the PB from
patients with ERA. Notably, phosphorylation of these signaling effectors did not distinguish ERA from late RA, suggesting
that the activation status of discrete cell populations is already established early in disease. However, when the ratio of MFI
values for p-AKT and p-p38 is .1.5, there is a high likelihood of having a diagnosis of RA. Our results suggest that
longitudinal sampling of patients undergoing therapy may result in phospho-signatures that are predictive of drug
responsiveness.
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Introduction
Rheumatoid arthritis (RA) is a common, relapsing autoimmune
disease primarily affecting the joints. RA affects approximately 1%
of the population worldwide [1]. The clinical manifestations
include joint swelling, deformity, pain, stiffness, and weakness [2].
Within the affected RA joint, there is proliferation of synovial
lining cells, pannus accumulation over articular cartilage and
erosion of the underlying bone. The rheumatoid synovium is an
area of intense immunological activity [3,4] with a profound
infiltration of inflammatory cells, including mononuclear cells and
lymphocytes, which occasionally form secondary lymphoid
structures [5]. Additionally, RA is not exclusively restricted to
the joints and other extra-articular manifestation occur and
account for considerable mortality and morbidity [6]. While the
specific molecular events that lead to initiation and onset of RA
are not known, a systemic activation of the immune system is
considered to be a critical component of the disease.
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6703The etiology of RA is unclear, however, many cells types
including fibroblast like synovial cells (FLS), B and T lymphocytes,
macrophages and neutrophils all contribute to joint inflammation.
Both T and B lymphocytes have prominent roles in RA pathology.
The genetic association of RA with specific HLA-DR1 underscores
theimportanceofT lymphocytesinRApathology[7].Additionally,
adoptive transfer of CD4+ T cells from affected animals induces
joint inflammation in healthy recipients [8], while blocking T cell
activationclearlyhasbeneficialconsequencesinhumanRApatients
[9]. Recently, a novel IL-17 secreting T cell subset (Th17) has been
implicated in RA disease pathogenesis in both human RA and in
mouse models of disease [10]. B lymphocytes undoubtedly play a
critical role in RA pathology, as autoantibodies are found in the
majority of patients [11,12] and B cell depletion with rituximab
results in significant improvement in disease symptoms [13].
Additionally, B cells maintain T cell activation in the RA joint
[14] and interactions between T and B cells may represent unique
events in autoimmune disease [11]. Taken together, the activation
of T and B lymphocytes may be early precipitating events in disease
pathology and, as such, may identify useful diagnostic markers of
disease initiation and/or progression.
Effective management of RA requires early diagnosis and timely
treatment to prevent significant joint destruction and improve
patient outcomes. Diagnosis of RA is difficult and is based on
specific clinical parameters, radiographic evidence of joint
destruction and/or the presence of anti-CCP/RF antibodies
[12,15]. The current criteria for diagnosis of RA have come
under scrutiny due to an inability to establish the diagnosis of RA
in the early stages of the disease [16]. While considerable progress
has been made in identifying predictive criteria for disease
progression [17,18], identification of definitive diagnostic markers
with higher sensitivity and specificity are required. Early aggressive
therapy with multiple DMARDs including biological agents is
highly effective in preventing disease progression [19]. Currently
there are no specific and/or rapid tests for monitoring disease
progression and/or responsiveness to therapy. Viewed altogether,
these deficiencies promoted the examination of patient cells for the
identification of early activation markers in RA.
Recent advances in flow cytometry have expanded the number
of simultaneous analyses to greater than 13, allowing for the
detection of both surface and intracellular factors, thereby
enabling identification of specific cell subsets as well as their
functional activation in a heterogeneous cell population. Phospho-
specific flow cytometry (phospho-flow) permits the quantification
of phosphorylation levels of intracellular signaling proteins in
individual cells, including rare populations of cells [20,21,22].
Phospho-flow is highly quantitative [21,23] and novel network-
based screens of complex populations in disease samples can easily
be obtained [20]. Phospho-flow technology has identify mutated
signaling pathways in leukemia [24], predicted responsiveness of
leukemic patients to chemotherapy [25] and can assess the
effectiveness of drug therapy in blocking cellular signaling [26].
Accordingly, we have employed phospho-flow technology to
analyze the peripheral blood (PB) of patients with early RA
(ERA) and established RA and compared the phospho-flow
signatures with those from the PB of patients with osteoarthritis
(OA) and healthy individuals. In addition, patients were stratified
according to medication status and phospho-specific activation
was used to examine responsiveness to specific therapies. This
exploratory study examined fifteen phospho-epitopes in 3 cell
lineages: CD3+CD4+, CD3+CD8+, and CD20+. The data
suggest that analysis of the phospho-activation status of the PB
leukocyte population may useful for monitoring disease activity
and/or responsiveness to therapy.
Results
Signaling profiles in RA joint T cells
At the outset, to confirm the activation status of T cells in RA in
the context of phosphorylation-activation, we employed a
customized BD PowerBlot immunoarray as a high throughput
Western blot screen for phosphorylated signaling effectors. 20
paired phospho-signaling effectors were evaluated. CD3+ T cells
were isolated from the affected joints of 3 patients with established
RA at the time of joint replacement and protein lysates prepared.
We identified elevated levels of phosphorylated (p)-AKT, p-p38, p-
JNK, p-STAT1, p-STAT3, p-STAT5, p-ATF2, p-cdc2, p-p120,
p-PKARIIb and p-src in joint infiltrating CD3+ T cells (Figure 1).
Notably, phosphorylation of src is consistent with T cell activation
[27].
Phosphorylation-activation of PB cell subsets in ERA, RA
and OA.
Next, multiparameter phospho-FACS was employed to analyze
the phosphorylation-activation status of specific signaling effectors
in the PB of patients with ERA, established RA and OA, gating on
CD3+CD4+, CD3+CD8+ and CD20+ cell populations. The 15
signaling effectors employed in this study were specifically chosen
as they are critical signaling nodes activated by multiple pathways
and are likely candidates as indicators of activation in multiple cell
populations. Multiple phospho-epitopes were activated in the
circulating CD4+ and CD8+ T cells and CD20+ B cells from ERA
(Figure 2) and established RA patients (data not shown) compared
with healthy individuals. Notably, p-AKT, p-CBL, p-JNK, p-
PLC-c, p-STAT1, p-STAT3, p-STAT6 and p-ZAP70 mean
fluorescent intensity (MFI) levels were significantly elevated in
ERA patient PB subsets in all three cellular compartments. The
MFI values were not significantly different between the ERA and
established RA patient PB subsets (Figure S1) for any of the 15
phospho-epitopes examined. Because this was an exploratory
study investigating the general utility of phospho-flow in diagnosis
and treatment, no correction for multiple comparisons was made
Figure 1. Phospho-specific epitopes are activated in RA
synovial tissue lymphocytes. Cell lysates were prepared from ST
lymphocytes isolated from the affected joints of 3 patients with late-
stage RA, at the time of joint replacement, as described in Methods.
Lysates were analyzed by a customized BD PowerBlot and data are
shown as mean6SE. Values represent the average intensity of triplicate
readings except for p-JNK, p-STAT5, p-cdc2 and p-src, which are
averages of duplicate samples.
doi:10.1371/journal.pone.0006703.g001
PBMC Phospho-Analysis in RA
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section on Statistical analysis). If we had corrected using the
Bonferroni correction for 45 comparisons (as shown in Figures 2
and 3), a p-value of less than 0.0011 would be considered
statistically significant. Rather than discourage the future study of
potentially valuable phospho-epitopes by applying such a
correction, we instead note that we have not adjusted for family-
wise error.
Next we examined whether phosphorylation of specific
signaling effectors was disease specific, by comparing the
phosphorylation profiles of PBMC from ERA and OA patients.
The MFI levels for p-AKT, p-CBL and p-JNK were statistically
higher (p,0.05) in ERA patient PBMCs compared with OA
patient PBMCs, in the CD4+, CD8+ and CD20+ compartments
(Figure 3). Additionally, the extent of phosphorylation-activation,
as measured by the number of phosphorylated signaling effectors
for which the MFI values were significantly different between ERA
and OA samples, was greatest in the CD4+ T cell population
(Figure 3). For each of the phospho-epitopes we next set an
arbitrary threshold MFI level that was 10% higher than the
maximum MFI level recorded amongst the healthy individuals
(Table 1). Our subsequent analysis, based on this threshold,
distinguished ERA patients with activated phospho-epitopes in all
three cell compartments (CD4+, CD8+ and CD20+) (Table 1). In
contrast, OA patients had fewer phospho-epitopes activated,
predominantly in the CD8+ T cell compartment (Table 1).
Further analysis directly comparing the ERA and OA patient
groups, again using a threshold of 10% greater than the highest
OA patient MFI value, provided evidence for a distinguishing
activation profile in the CD4+ T cells and CD20+ B cells in
patients with ERA (Table 2). The data in Figure 4A reveal a
significant difference (p,0.001) in the ratio of the CD8 range/
CD4 range for p-AKT, p-CBL, p-H3, p-PLCc and p-ZAP70
between RA and OA patients.
Scrutiny of ratios of MFI values between pairs of different
phosphorylated signaling effectors identified that p-AKT and p-
p38 ratios as well as p-JNK and p-p38 ratios distinguished between
ERA and OA patients (Figure 4 B, C). Since p-p38 MFI values
remained fairly constant across the control, OA and ERA patient
specimens, we postulated that p-p38 serves as an internal control
to normalize individual samples. Significant differences in the p-
AKT/p-p38 ratios were observed in ERA compared with OA in
the CD4+, CD8+ and CD20+ cell populations (Figure 4B,
p,0.05), whereas the p-JNK/p-p38 ratios were significantly
different in the CD4+ and CD8+ populations only (Figure 4C,
p,0.05). There were no significant differences in these phospho-
pair ratios between the OA and healthy individual cohorts, for any
of the three cell types. As anticipated, examination of these
phospho-pair ratios in RA patients with established disease, in
their PB CD4, CD8 and CD20 cells likewise distinguished RA
Figure 2. Distinct PBMC subsets in ERA are activated. PBMCs from patients with ERA (n=10, closed circles) and healthy individuals (n=10,
open circles) were analyzed by multiparameter phospho-FACS, gating on CD3+CD4+, CD3+CD8+ and CD20+ cell populations, as indicated.
Scatterplots of the MFI for15 phospho-specific epitopes are shown. Significant differences in MFI values were calculated by Student’s t test (p,0.05).
doi:10.1371/journal.pone.0006703.g002
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shown). The diagnostic potential of this phospho-epitope ratio was
assessed by calculating the percentage of patients with a p-AKT/
p-p38 ratio or a p-JNK/p-p38 ratio greater than 1.5. A p-AKT/p-
p38 ratio .1.5 was observed in 90% (9/10) of ERA patients and
80% (4/5) of RA patients with established disease, in the CD4,
CD8 and CD20 PB cell populations. Notably, this threshold of
.1.5 was only exceeded in one of the 10 (10%) healthy individuals
in their CD20 cells. For the OA cohort, this ratio was exceeded in
one (11%) of the CD4 samples and 2 (22%) of the CD8 and CD20
samples. A p-JNK/p-p38 ratio .1.5 was observed in PB CD4,
CD8 and CD20 cells in 70% (7/10), 90% (9/10) and 50% (5/10)
of ERA patients, respectively. p-JNK/p-p38 ratio .1.5 was
observed in 80% (4/5), 60% (3/5) and 80% (4/5) of RA patients
with established disease in their PB CD4, CD8 and CD20 cells,
respectively. p-JNK/p-p38 ratio .1.5 was observed in 11% (1/9),
22% (2/9) and 22% (2/9) of OA patients in their PB CD4, CD8
and CD20 cells, respectively. None of the healthy individuals had
p-JNK/p-p38 ratios .1.5.
p-H3 and p-AKT levels correlate with physician global
assessment and DAS
In the next series of analyses, with specimens acquired from a
distinct cohort of patients, we examined whether there existed a
correlation between phosphorylation status in defined cell
populations and disease activity. Clinical parameters measuring
disease status (DAS28, physician global assessment (MDGA), CRP
and ESR levels) were compared to phospho-activation levels.
Correlations were observed between phospho-histone (H3) and p-
AKT levels in the CD4+, CD8+ and CD20+ populations in the PB
of ERA patients and their MDGA scores (Figure 5). Moreover, the
extent of phosphorylation of H3 and AKT in the CD4+,CD8+
and CD20+ cells of the PB of ERA patients also directly correlated
with DAS28 (Figure 5).
Effects of drug therapy on PBMC phospho-activation
profile
We next examined the effects of specific disease modifying anti-
rheumatic drugs (DMARDs) on the phosphorylation status of 12
phospho-epitopes in ERA patients. As a first screen, patients were
grouped according to whether they were receiving a particular
DMARD or not, regardless of whether a patient was on
monotherapy or not. All patients in the drug study cohort were
on some form of drug therapy (refer to Table S1). The effects of
the non-steroidal anti-inflammatory drugs (NSAID), methotrexate
(MTX), sulphasalazine (SSZ), plaquenil (HCQ) and leflunomide
(LEF), systemic steroids (predominantly prednisone), TNF inhib-
itors (Enbrel or Humira), and intra-articular (IA) steroids, were
assessed. Notably, TNF inhibitors, LEF, systemic steroids and
MTX therapy resulted in decreased activation of multiple
Figure 3. Distinct phosphorylation signatures between ERA and OA PBMCs. PBMCs from patients with ERA (n=10, closed circles) and OA
(n=9, open circles) were analyzed by multiparameter phospho-FACS, gating on CD3+CD4+, CD3+CD8+ and CD20+ cell populations, as indicated.
Scatterplots of the MFI for 15 phospho-specific epitopes are shown. Significant differences were calculated by Student’s t test (p,0.05).
doi:10.1371/journal.pone.0006703.g003
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were observed in the PBMC of patients on LEF (Figure 6, Figure
S2) or systemic corticosteroids (Figure 6, Figure S3), compared to
those patients not taking these specific DMARDs. Notably, 3 of
the 5 patients on LEF were also receiving Enbrel. Interestingly, the
phospho-activation signatures for each drug were not identical and
patients on LEF exhibited reductions in p-STAT6 in their CD20+
B cells and reduced p-PLC-c in their CD4+ and CD8+ T cells,
while patients on systemic steroids showed decreases in p-BTK
and p-JNK in their CD4+ cells, p-ERK, p-p38 and p-STAT3 in
their CD20+ cells, and p-STAT4 in their CD4+ and CD8+ cells.
Patients on TNF inhibitors (Enbrel or Humira) exhibited
significant reductions in levels of p-AKT, p-BTK, p-ERK, p-
JNK, p-p38, p-PLCc, pSTAT1, p-STAT3, p-STAT5 and p-
STAT6 in their CD4+ cells (Figure 6, Figure S4). Reductions in
MFI values for p-AKT, p-p38, p-JNK, p-PLCc, and p-STAT5
were also observed in their CD8+ cells and reductions in p-p38
were observed in their CD20+ cells.
There were no significant differences in the MFI values between
patients prescribed NSAIDS (Figure 6, Figure S5), HCQ (Figure 6,
Figure S6) or sulphasalazine (SSZ) (Figure 6, Figure S7) for any of
the 12 phospho-epitopes in any of the cell types. Patients receiving
IA steroids showed significant reductions in p-H3 in their CD4+,
CD8+ and CD20+ cells (Figure 6, Figure S8). MTX therapy
reduced p-STAT1 MFI values in CD20+ cells (p=0.045) (data not
shown). Given the effects of LEF and systemic steroid therapy on
the activation profile of PBMCs, we re-examined the effects of
MTX therapy on phosphorylation status, removing patients on
LEF or systemic steroid therapy from these analyses. Our analysis
revealed significant reductions in the phosphorylation of AKT and
H3 in the PBMC CD4+ cells (Figure S9) but no change in the
reduction in p-STAT1 observed in the CD20+ cells. However,
reductions in CD20+ cell p-AKT and p-H3 and CD8 cell p-AKT
were revealed.
In a final analysis of these data, we investigated the utility of
phosphoflow measurements as correlates of patient responsiveness
to therapy. The majority of patients in this study were responding
to therapy, as shown by their decreases in DAS (21.7860.42,
n=23). Changes in DAS were assessed by subtracting the DAS at
the time of sampling with the baseline DAS at their first clinic visit.
Of note, some patients were only sampled at their baseline visit
and, as such, a delta DAS could not be calculated. Given that anti-
TNF therapy affected phospho-signaling effectors to the greatest
extent and 3 of the 4 patients on anti-TNF therapy started therapy
after their first clinic visit, we selected the data from this cohort for
analysis. Patients receiving anti-TNF therapy had an overall
decrease in the total tender joint count (TJC), swollen joint count
(SJC) and DAS28 (Figure 7A). We observe a high degree of
correlation between the DAS and MFI values for p-AKT
(Figure 7C) and p-H3 (Figure 7B). These preliminary data suggest
that phosphoflow analysis of a limited number of signaling
effectors may be reflective of drug responsiveness, at least in the
context of anti-TNF therapy, the subject of our ongoing
investigations.
Discussion
RA is a complex, polygenic autoimmune disease that progresses
over decades and involves many different cell types, including both
resident and recruited cells. Early diagnosis of RA is difficult since
there is no single test, but a combination of predictive indices,
incorporating clinical parameters, radiographic evidence of joint
destruction and the presence of anti-CCP and RF antibodies. The
identification of specific activating events that play a role in the
pathogenesis and/or progression in RA would be invaluable for
both diagnosis and monitoring responsiveness to therapy. Herein,
we describe the use of phospho-flow analysis to quantitatively
analyze multiple phospho-epitopes as indicators of PB lymphocyte
activation.
Lymphocyte infiltration in the RA synovium is observed as
either a diffuse inflammatory infiltrate or as clusters of lymphoid
follicular aggregates. In some patients, these aggregates exhibit
germinal centre-like activity. T cells in affected RA joints show
signs of prior activation, are hyporesponsive to antigenic
stimulation [28] yet resistant to apoptosis [29,30]. While we did
not compare the level of activation of joint T cells to other
inflammatory conditions, our data support previous studies that
Table 1. Elevated phosphorylation of signaling effectors in
ERA and OA PB CD4+, CD8+ and CD20+ populations.




ERA p-AKT 90% 80% 70%
ERA p-BTK 70% 70% 50%
ERA p-CBL 70% 70% 60%
ERA p-H3 50% 50% 40%
ERA p-JNK 90% 80% 70%
ERA p-PLCc 70% 60% 60%
ERA p-STAT1 80% 70% 70%
ERA p-STAT3 70% 70% 70%
ERA p-STAT4 0% 60% 0%
ERA p-STAT6 70% 70% 60%
ERA p-ZAP70 70% 70% 70%
OA p-BTK 0% 44% 0%
OA p-JNK 0% 0% 44%
OA p-STAT1 0% 44% 0%
OA p-STAT3 44% 44% 0%
OA p-STAT4 0% 44% 0%
OA p-STAT6 44% 44% 0%
*Percentage of patients with MFI values $10% above the maximum level
recorded in the healthy individual cohort is denoted.
doi:10.1371/journal.pone.0006703.t001
Table 2. ERA PB phospho-signaling is distinguished from OA





p-AKT 50% 0% 40%
p-BTK 50% 0% 40%
p-CBL 60% 0% 40%
p-JNK 50% 0% 0%
p-PLCc 60% 0% 40%
p-STAT1 50% 0% 40%
p-STAT3 40% 0% 0%
p-STAT6 40% 0% 40%
p-ZAP70 50% 0% 40%
*Percentage of ERA patients with MFI values $10% above the maximum level
recorded in the OA patient cohort is denoted.
doi:10.1371/journal.pone.0006703.t002
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range/CD4 MFI range for each of p-AKT, p-CBL, p-H3, p-PLCc and p-ZAP70 and (B) to compare the p-AKT/p-p38 and p-JNK/p-p38 ratios, between ERA
(n=10) and OA (n=9) patients, in the indicated cell populations. Significant differences were determined by ANOVA followed by Tukey’s multiple
comparison (p,0.05).
doi:10.1371/journal.pone.0006703.g004
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IL-1, cytokines implicated in disease development, induce
activation of these signaling effectors [32]. In addition to p38
and JNK MAPK activation, we observed AKT and STAT
activation in CD3+ lymphocytes. AKT promotes cell survival, and
MAPKs and STATs are associated with induction of cytokine
gene expression, from which we infer that these RA PB
lymphocytes may actively participate in the inflammatory
response. Whether lymphocyte activation also occurs in the
circulation, prior to arrival in the joint, is the subject of these
investigations. PB sampling is less invasive than sampling affected
joints, and here we show a similar activation profile in ERA
PBMCs, from which we infer that lymphocyte activation may
precede joint infiltration. While additional validation studies are
still required, PB lymphocyte activation may be a reliable
indicator/predictor of joint inflammation.
Notably, there were no significant differences in phosphoryla-
tion profiles between ERA and established RA PBMCs. The initial
stages of autoimmunity involve a breakdown of B and T cell
tolerance and in RA this is manifested by measurable levels of
serum anti-CCP and/or anti RF antibodies, which are detected
years before the onset of articular symptoms [33]. For individuals
to have an ERA diagnosis they must satisfy ACR criteria, by which
time the mechanisms driving RA are already well established.
Since the early RA joint cytokine profile is unique (Th2 skewed)
[33], retrospective analysis of inflammatory arthropathies at earlier
stages may provide insights into the dynamic changes in PBMCs at
the onset of autoimmune disease.
Given the critical roles of CD4+ T cells and CD20+ B cells in
autoimmune disease pathology, monitoring dynamic changes in
these cell populations may provide insights into disease progres-
sion. The 15 signaling effectors employed in this study were
specifically chosen as they are critical signaling nodes activated by
multiple pathways and as such are likely candidates as indicators of
activation in multiple cell populations. Specific signaling effectors
(AKT, CBL, JNK, PLC-c and STAT1) were significantly
activated in the PBMC of ERA patients compared with healthy
individuals. The MFI values of a subset of these effectors, p-AKT,
p-CBL and p-JNK, were consistently higher in all three cell
populations in ERA patient PBMCs compared to OA patient
Figure 5. The extent of phosphorylation of H3 and AKT correlates with the MDGA score and DAS28 in ERA PBMC. Dot plots of (A)
MDGA vs p-H3 MFI values (n=32) and (B) MDGA vs p-AKT MFI values (n=32) in the CD4, CD8 and CD20 cell populations of ERA patient PBMC.
doi:10.1371/journal.pone.0006703.g005
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significantly elevated phospho-signaling effectors (Figure 3), un-
derscoring the importance of these cells in autoimmunity.
Additionally, a higher percentage of ERA patients showed
phospho-activation in their PB CD20+ cells, consistent with B
cell hyperreactivity distinguishing RA from OA [11,12]. However,
given the variability across the OA and ERA samples, no single
phospho-epitope emerged as a unique diagnostic. Further studies
examining the activation status of specific cellular subsets such as
CD4+Th17 cells, which are elevated in the circulation of RA
patients [34,35], may be indicative of disease stage and activity.
While single phospho-epitopes were not diagnostic, p-AKT:p-p38
ratios and p-JNK:p-p38 ratios .1.5 distinguished between ERA
and OA patients (Figure 4B, C). These ratios may be easily
adapted into part of a clinical screening regime for the diagnosis of
RA.
Our analysis included an examination of correlates between
measures of disease activity and severity, or disease status, and
levels of phosphorylation of signaling effectors in the different PB
cell compartments. We identified correlations between the extent
of phosphoryation of AKT and H3 in the CD4+, CD8+ and
CD20+ PB cells of ERA patients and their MDGA score and
DAS. AKT is a signaling effector associated with cell survival, cell
proliferation and cytokine production. Both TNF and IL-17
induce signaling cascades that involve AKT activation. H3
phosphorylation is associated with gene transcription and cell
division [36] and the correlation with MDGA score or DAS may
point toward expansion of these cell populations.
Currently, factors that are predictive of ‘severity to be’ or
responsiveness to particular therapeutic regimens remain, in the
main, indicators of likelihood/probability, based on aggregate not
individualized data. Many factors have been reported to predict
disease progression, responsiveness to therapy or remission,
including antibody levels to citrullinated peptides [37,38] and
citrullinated fibrinogen [39], low baseline serum soluble IL-2
receptor levels [40], early response to DMARD treatment [41,42],
the active joint count [43] or urinary levels of C-terminal
crosslinking telopeptide of type 1 (CTX-I) and type II (CTX-II)
[44]. Generally, RA patients with longer disease duration do not
respond as well to treatment compared with patients with early
disease, and female sex, prior DMARD use and disease activity
[45]. In this context, molecular markers that are accurately
predictive in an individual of high risk of rapid progression as well
as responsiveness to a particular drug therapy are still required.
Early aggressive treatment of RA is associated with beneficial
patient outcomes and there is an accumulating consensus that
Figure 6. Drug therapy affects the phosphorylation levels of signaling effectors in ERA PBMC. Hierarchical clustering heatmap showing
the level of statistical significance, as a p value, for the difference in MFI values for each indicated phospho-signaling effector comparing patients on
therapy versus patients not on therapy. Statistical differences were calculated by Student’s t test.
doi:10.1371/journal.pone.0006703.g006
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aggressive treatment of RA can produce permanent remission
[46]. Early MTX treatment slows disease progression and is the
first drug of choice for RA [47,48]. However, not all patients are
responsive to MTX and approximately 50% of patients are
refractory to anti-TNF therapy [49]. Current clinical practice
involves monitoring therapeutic improvements over several
months, whereas phospho-flow analysis represents a rapid
alternative. Specifically, medication-induced changes in signature
signaling phospho-epitope profiles are rapid. Although in our
study cohort the majority of patients were on multiple medications
(Table S1), data analysis distinguished the contributions of LEF,
corticosteroids, MTX and anti-TNF therapy as signature
reductions in phosphorylation profiles.
LEF, MTX and corticosteroids are broad immunosuppressive
agents that reduce pain and swelling of affected joints, reduce
cytokine production and limit radiological damage
[50,51,52,53,54,55]. In addition, LEF blocks T and B cell
proliferation and activation [56,57,58], inhibits TNF dependent
NF-kB signaling, reduces matrix metalloproteinase expression and
inflammatory cytokine production [51,59,60,61,62]. Consistent
with published data [63], we provide evidence that LEF reduces p-
STAT6 levels in CD20+ B cells, which may direct reductions in
antibody production. Interestingly, prednisone reduced p-STAT3
levels, and recent data suggest that steroid treatment causes
reductions in IL-17 production [64]. Cognizant that STAT3
activation is critical for the development of IL-17 producing T cells
[65,66], it is intriguing to speculate that LEF and prednisone
Figure 7. Phosphorylation levels correlate with changes in DAS28. (A) Changes in tender joint count (TJC), swollen joint count (SJC) and
DAS28 between the time of sampling and baseline scores are recorded for TNF inhibitors (TNFi) (n=5, Enbrel or Humira), LEF (n=6) and systemic
steroids (n=5). Values are the mean6SE. MFI values for (B) p-H3 (n=4) and (C) p-AKT (n=4) are plotted relative to changes in DAS in the PB CD4, CD8
and CD20 cell compartments, as indicated.
doi:10.1371/journal.pone.0006703.g007
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ylation-activation of STAT3. Additionally, LEF inhibits Th17
generation through inhibition of p-STAT6 [67] and we also
observed reductions in p-STAT6 levels in patients on these
medications. Notably, p-STAT4 levels were dramatically reduced
in both the CD4+ and CD8+ T cells in patients on steroid therapy.
Certainly, STAT4 has been associated with an increased risk of
RA and mice lacking STAT4 are resistant to experimental
arthritis [68]. STAT4 expression in joints of patients with ERA has
been reported [69] and here we show that prednisone may
function in part by blocking STAT4 activation.
Despite its widespread use as a therapy for RA, the mechanisms
of action of MTX are complex and not entirely characterized [55].
MTX inhibits dihydrofolate reductase and limits cell proliferation
[55]. Therefore, we had anticipated that patients on MTX therapy
would exhibit reductions in multiple phospho-signaling effectors,
as was the case. Significant reductions in p-AKT and p-H3 MFI
values correlated with disease scores. MTX reduces JAK/STAT
activation within the joints [70]. Notably, MTX treatment did
reduce the levels of phosphorylation of AKT and STAT1.
Results from more than a decade of clinical trials has provided
compelling evidence that TNF inhibitors reduce disease activity
and delay joint damage [71]. TNF activates multiple kinases (p38,
ERK, JNK) and will induce the expression of other pro-
inflammatory cytokines that, in turn, invoke pro-inflammatory
signaling events associated with kinase activation. Therefore, the
substantive therapeutic effects of anti-TNF therapy are a
consequence of both direct inhibition of TNF and a blockade of
TNF-inducible other pro-inflammatory cytokines. TNF blockade
leads to more profound anti-inflammatory outcomes than
conventional DMARDs [72] and herein we show that anti-TNF
therapy reduced phosphorylation levels of signaling effectors to a
greater extent than other DMARDs. Notably the anti-TNF
therapy was predominantly initiated during the course of this
study, therefore, it is possible that the potency of this drug and
sampling close to initiation of therapy gave the most significant
effects.
Viewed altogether, these data demonstrate the utility of multi-
parameter phospho-flow analysis for monitoring the activation
status of discrete PB cell populations in ERA. Quantitative
examination of the extent of phosphorylation of critical signaling
effectors has the potential to be diagnostic for RA. Moreover, we
provide preliminary evidence that reductions in the extent of
phosphorylation of these biomarkers may predict responsiveness to
drug therapy. Our results suggest that longitudinal sampling of
patients undergoing therapy may result in phospho-signatures that
not only correlate with drug responsiveness but also may predict
patient responsiveness to a specific class of drug. Our ongoing
studies are directed to extending these observations in a larger
prospective cohort of ERA patients.
Materials and Methods
Patients
Sample collection involved confirmation of the diagnosis of RA
and OA using clinical, serologic and radiological data. Informed
written consent was obtained from all study participants and
institutional approval was granted by the Mount Sinai Hospital,
St. Michael’s Hospital and Sunnybrook and Women’s College
Health Sciences Centre ethics committees (Toronto, ON). Early
RA was defined as patients within the first year following the onset
of symptoms with a minimum of 3 swollen joints. Both ERA and
established RA patients were diagnosed according to the
American College of Rheumatology 1987 revised criteria [15].
The study included a total of 38 ERA patients, 10 late RA
patients, 19 OA patients and 10 control, healthy individuals (non-
RA, non-OA). The average age of patients in this study was 44.1
years for ERA (range 17–73) and 57.0 years for late RA (range 36–
72) with a median disease duration of ,1 year for early RA and 10
years for late RA. Clinical parameters were recorded at the time of
sample collection and are summarized in Table 3. Multiple
samples were collected from some ERA patients and almost all
patients in this study were receiving medication (Table S1).
Synovial tissue
RA synovial tissue (ST) samples (n=3) were collected from
patients with erosive, end-stage RA at the time of joint
replacement surgery. All ST specimens were immediately
transferred to research personnel for processing.
Blood collection
Human PB was collected into heparinized vacutainer tubes and
PBMCs were isolated by Ficoll gradient centrifugation at 800 g for
20 minutes. The PBMC layer was washed, counted, resuspended
in 90% human serum (Irvine Scientific, Irvine, CA) and 10%
DMSO (Sigma, St Louis, MO) and frozen in liquid nitrogen to
maintain cellular activation levels. Blood samples from control,
healthy adults (University Health Network, Toronto) were handled
and processed in parallel.
Cell surface and intracellular phospho-specific flow
cytometry
For flow cytometric analysis, human PBMCs were thawed at
37uC, washed twice and incubated for 1 hour. PBMC were then
fixed in 2% paraformaldehyde at 37uC for 10 minutes. Cells were
counted, pelleted and resuspended at 1610
7/ml in FACS buffer.
Cells were washed and permeabilized with 90% ice-cold methanol
for 15 min: PBMCs were stained with directly conjugated
antibodies against CD4 (RPA-T4), CD8 (RPA-T8), CD20 (L27)
and phospho-epitopes (Becton-Dickinson; San Jose, CA, unless
otherwise specified) as previously described [22](Table S2).
Intracellular stains consisted of phospho-specific proteins for p-
AKT (Biosource, pS473), p-BTK (pY551), p-PLC-c (pY783), p-cbl
(pY700), p-H3 (Cell Signaling Technology, pSer10), p-JNK
(Biosource, pTpY183/185), p-p38 (pT180/Y202), p-p44/42
(pT201/Y202), p-lck (pY505), p-ZAP70 (pY319), p-STAT1
(pY701), p-STAT3 (pY705), p-STAT4 (pY693), p-STAT5
(pS727) and p-STAT6 (pY641). Cells were washed twice and
100,000-500,000 cells were acquired on an LSRII FACS machine
operated at Stanford University (12 color, BD Biosciences)
acquired with DiVa software (Beckton Dickinson) and analyzed
with Flojo (Treestar). Data were acquired on an initial set of
samples (controls n=10, ERA n=10, RA n=5, OA n=9) and a
second and larger cohort of samples (ERA n=40, RA n=10, OA
n=10) was used to assess correlations and drug related effects.
Synovial lymphocyte isolation and BD PowerBlot analysis
CD3+ T cells from ST from affected RA joints were isolated by
enzymatic digestion with collagenase I, II, IV (3 mg/g tissue) and
DNase (2 mg/g tissue) for 0.5–2 hours at 37uC, depending on the
sample size. Single cell suspensions were collected after straining
the digest through a 70 mm filter. T cells were purified by negative
selection, using 0.10 StemSep magnetic columns and antibodies
against CD32, CD19, CD56, CD66b, glycophorin A, 5E11 and
dextran. Contaminating macrophages were removed by 2 hour
incubation on tissue culture plastic. CD3+ T cell lysates were
collected in lysis buffer (10 mM Tris,pH 7.4, 1 mM sodium
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samples (200 mg) were resolved by electrophoresis on a 4–15%
gradient SDS-polyacrylamide gel and transferred onto an
Immobilon-P membrane (Millipore) and analyzed as previously
described [73]. Samples were analyzed by a customized
phosphoprotein BD array using the average of duplicate (n=2)
or triplicate (n=1) readings. 57 proteins were assessed in these
arrays.
Statistical analysis
Results are expressed as the mean6SE, unless otherwise
indicated. Populations were compared with Student’s t-test with
no assumption of equal variance, unless otherwise noted. P-values
less than 0.05 were considered statistically significant. Correlation
coefficients and associated p-values were computed using linear
regression. ANOVA was performed on samples with multiple
groups followed by Tukey’s Multiple Comparison test. Statistical
tests were performed using either the R environment for statistical
computing (www.r-project.org) or Prism (GraphPad Software, San
Diego CA).
Supporting Information
Figure S1 PBMC activation patterns are similar in RA and
ERA. PBMCs from patients with RA (n=5, open circles) and
ERA (n=10, closed circles) were analyzed by multiparameter
phospho-FACS, gating on CD3+CD4+, CD3+CD8+ and CD20+
cell populations, as indicated. Scatterplots of the MFI for 15
phospho-specific epitopes are shown. No significant differences in
MFI values were identified, calculated by Student’s t test (p,0.05).
Found at: doi:10.1371/journal.pone.0006703.s001 (2.37 MB TIF)
Figure S2 LEF affects the phosphorylation status of ERA
PBMCs. PB MFI values for each of the indicated phospho-
epitopes are plotted to compare ERA patients on LEF (n=6
except for p-AKT, p-BTK and p-H3 where n=4; open circles)
versus those not receiving this DMARD (n=31 except for p-JNK,
p-p38 and p-STAT3 where n=30 and p-AKT, p-BTK and p-H3
where n=19; closed circles). Data are shown for each of the
indicated cell populations. Significant differences were calculated
by Student’s t test (p,0.05).
Found at: doi:10.1371/journal.pone.0006703.s002 (1.02 MB TIF)
Figure S3 Systemic steroids affect the phosphorylation status of
ERA PBMCs. PB MFI values for each of the indicated phospho-
epitopes are plotted to compare ERA patients on systemic steroids
(n=9 except for p-AKT, p-BTK and p-H3 where n=6; open
circles) versus those not (n=28 except for p-JNK, p-p38 and p-
STAT3 where n=27 and p-AKT, p-BTK and p-H3 where
n=17; closed circles). Data are shown for each of the indicated
cell populations. Significant differences were calculated by
Student’s t test (p,0.05).
Found at: doi:10.1371/journal.pone.0006703.s003 (1.12 MB TIF)
Figure S4 TNF inhibitors lower the activation status of ERA
PBMCs. PB MFI values for each of the indicated phospho-
epitopes are plotted to compare ERA patients on TNF inhibitors
(n=5 except for p-AKT, p-BTK, p-JNK, p-p38, p-H3 and p-
STAT3 where n=4; Enbrel or Humira, open circles) versus those
not receiving anti-TNF therapy (n=32, except for p-AKT, p-BTK
and p-H3 where n=19; closed circles). Data are shown for each of
the indicated CD4+ cell populations. Significant differences were
calculated by Student’s t test (p,0.05).
Found at: doi:10.1371/journal.pone.0006703.s004 (1.18 MB TIF)
Figure S5 NSAID therapy does not affect phosphorylation-
activation in ERA PBMCs. PB MFI values for each of the indicated
phospho-epitopes are plotted to compare ERA patients on NSAIDs
(n=20 except for p-JNK, p-p38 and p-STAT3 where n=18 and p-
AKT, p-BTK and pH3 where n=12; open circles) versus those not
(n=17 except for p-AKT, p-BTK and p-H3 where n=11; closed
circles). Data are shown for each of the indicated cell populations.
NSAIDS included ibuprophen, naprosyn, Arthrotec, Diclonefac,
Bextra, Celebrex, Mobicox, Meloxicam and Vioxx. Significant
differences were calculated by Student’s t test (p,0.05).
Table 3. Patient demographic and clinical characteristics
Control (n=10) ERA (n=44
#) RA (n=10) OA (n=19)
Age (years) 33.168.2 44.1614.7 57.0610.7 71.469.9
Sex (M/F) 4/6 3/41 1/9 8/11
Anti-RF
+ pos/neg ND 4/31 6/2 0/16
Anti-CCP+ ND ND 9/25 ND
Mean TJC ND 7.967.4 (n=49) ND ND
Mean SJC ND 6.367.1 (n=49) ND ND
Mean HAQ score ND 0.660.65 (n=48) 1.73660.33 (n=6) ND
Mean MDGA score ND 3.862.5 (n=49) 7.6062.77 (n=4) ND
Mean ESR (mm/hr) ND 17.6624.1 (n=46) 30.2615.5 (n=6) 16.8613.4 (n=14)
CRP (mg/L) ND 11.9632.6 (n=42) 16.9618.1 (n=8) 4.362. 8 (n=17)
WBC (610
9/L) ND 7.162.3 (n=46) 7.6062.76 7.9162.05
% on corticosteroids ND 20% (n=40) 37.5% (n=8) 0% (n=11)
% on MTX ND 45% (n=40) 66.7 (n=9) 0% (n=11)
RF , rheumatoid factor- negative result is ,20 IU/ml; CCP , anti-cyclic citrullinated peptide antibody positive; TJC , tender joint count; SJC , swollen joint count;
HAQ , Health Assessment Questionnaire; MDGA , physician’s global assessment, ESR , erythrocyte sedimentation rate; CRP , C Reactive protein; WBC , white blood
cell count; corticosteroids included prednisone and florinef;
#, 5 patients were sampled on 2 separate occasions.
ND , not determined.
*data are shown as mean6SD.
doi:10.1371/journal.pone.0006703.t003
PBMC Phospho-Analysis in RA
PLoS ONE | www.plosone.org 11 August 2009 | Volume 4 | Issue 8 | e6703Found at: doi:10.1371/journal.pone.0006703.s005 (2.43 MB TIF)
Figure S6 The effects of Plaquenil therapy on phospho-signaling
in ERA PBMCs. PB MFI values for each of the indicated
phospho-epitopes are plotted to compare ERA patients on
plaquenil (n=22 except for p-AKT, p-BTK and p-H3 where
n=14; open circles) versus those not (n=15 except for p-JNK, p-
p38 and p-STAT3 where n=14 and p-AKT, p-BTK and p-H3
where n=9; closed circles). Data are shown for each of the
indicated cell populations. Significant differences were calculated
by Student’s t test (p,0.05).
Found at: doi:10.1371/journal.pone.0006703.s006 (2.41 MB TIF)
Figure S7 The effects of Sulphasalazine therapy on phospho-
signaling in ERA PBMCs. PB MFI values for each of the indicated
phospho-epitopes are plotted to compare ERA patients on
sulfasalazine (n=9 except for p-AKT, p-BTK and p-H3 where
n=4; open circles) versus those not (n=28 except for p-JNK, p-
p38 and p-STAT3 where n=27 and p-AKT, p-BTK and p-H3
where n=19; closed circles). Data are shown for each of the
indicated cell populations. Significant differences were calculated
by Student’s t test (p,0.05).
Found at: doi:10.1371/journal.pone.0006703.s007 (2.32 MB TIF)
Figure S8 The effects of IA steroid therapy on phospho-
signaling in ERA PBMCs. PB MFI values for each of the indicated
phospho-epitopes are plotted to compare ERA patients on intra-
articular (IA) steroids (n=17 except for p-JNK, p-p38 and p-
STAT3 where n=16 and p-AKT, p-BTK and p-H3 where
n=11; open circles) versus those not (n=20 except for p-AKT, p-
BTK and p-H3 where n=12; closed circles). IA steroids included
DepoMD, Kenalg1 and dexamethasone. Data are shown for each
of the indicated cell populations. Significant differences were
calculated by Student’s t test (p,0.05).
Found at: doi:10.1371/journal.pone.0006703.s008 (2.33 MB TIF)
Figure S9 Methotrexate therapy decreases phospho-signaling in
ERA PBMCs. PB MFI values for each of the indicated phospho-
epitopes are plotted to compare ERA patients on MTX (no LEF
or systemic steroids) (n=15 except for p-JNK, p-p38 and p-
STAT3 where n=13 and p-AKT, p-BTK and p-H3 where n=8;
open circles) versus those not (n=12 except for p-AKT, p-BTK
and p-H3 where n=9; closed circles). Data are shown for each of
the indicated cell populations. Significant differences were
calculated by Student’s t test (p,0.05).
Found at: doi:10.1371/journal.pone.0006703.s009 (2.42 MB TIF)
Table S1 Patient medication
Found at: doi:10.1371/journal.pone.0006703.s010 (0.08 MB
DOC)
Table S2 Staining panel for phospho-specific profiling of PB
leukocyte subsets. Phospho-specific stains are shown in bold.
Found at: doi:10.1371/journal.pone.0006703.s011 (0.03 MB
DOC)
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